Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunovia AB ( (SE:IMMNOV) ) just unveiled an update.
Immunovia has been selected to present its clinical data at the EDRN Scientific Workshop in the US, highlighting the scientific progress and momentum behind its PancreaSure diagnostic test for early pancreatic cancer detection. This selection underscores Immunovia’s commitment to advancing early cancer detection through robust clinical science and affirms the credibility of its data, marking a significant acknowledgment of its efforts in the field.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes simple testing to detect proteins and blood-based antibodies indicating high-risk individuals for pancreatic cancer. Immunovia collaborates with healthcare providers, experts, and patient advocacy groups to make its test available to those at increased risk, with the USA being the largest market for pancreatic cancer detection.
Average Trading Volume: 4,039,736
Current Market Cap: SEK107.9M
Learn more about IMMNOV stock on TipRanks’ Stock Analysis page.